Yes this is exactly what we need posted here!
Post# of 263
(Total Views: 231)
Posted On: 07/15/2025 10:13:05 AM
Re: chuckles759 #223
Yes this is exactly what we need posted here!
“But none of that happened. In fact, the very opposite occurred. They were unable to deal with or even process the effects of the pandemic. Those individuals who managed the approval process of leronlimab had no regard for the drug at all and could not understand the pertinent data behind the drug if it bit them in the ass. Hearing their scoffing now proves too much to bear, and the motivation behind that disdain remains unclear, but certainly, a Nobel prize was not what they were after. Instead, they preferred to be depositioned and subpoenaed.”
“But none of that happened. In fact, the very opposite occurred. They were unable to deal with or even process the effects of the pandemic. Those individuals who managed the approval process of leronlimab had no regard for the drug at all and could not understand the pertinent data behind the drug if it bit them in the ass. Hearing their scoffing now proves too much to bear, and the motivation behind that disdain remains unclear, but certainly, a Nobel prize was not what they were after. Instead, they preferred to be depositioned and subpoenaed.”
(0)
(0)Vg Total Stock Market ETF (VTI) Stock Research Links
Daniel Rizzo
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
Headquarters: Washington, DC
Mailing & correspondence: 1930 18th St NW Suite B2 PMB 2161, Washington DC 20009
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
Principal Investigator:
FG001|FG002|FG003
https://firegatebiotech.com/2025
FG-001: Integrated Triplet Immunotherapy for Functional HIV Cure
FG-002: Triplet Immunologic Modulation in Oncology — NF-κB / IL-1Ra Axis
FG-003: Neuro-Immune Repair Triplet — Concept and Combination Framework
CCR5 Antagonists & Triplet Immunotherapy Synergy in HIV
HIV Cure Pathways — Functional-Cure Framework Overview
FG-003 Neuro-Immune Repair Triplet — IP & Combination Strategy
— Jeremiah 51:36
Founder & CEO | FireGate Biotech™
AI Platform: Lux Veritas™
Federal Whistleblower Case References
• HHS & SEC Whistleblower ID – HL-1412396
• DOJ Investigation Report / Whistleblower ID – 20250705-0001
• NIH Case Reference – CS1137565 ( IC IG / 50 U.S.C. § 3033 )
Website: FireGateBiotech.com
Headquarters: Washington, DC
Mailing & correspondence: 1930 18th St NW Suite B2 PMB 2161, Washington DC 20009
(For official updates and correspondence — I will no longer be posting here or responding via DMs)
Contact FireGate Biotech
Principal Investigator:
FG001|FG002|FG003
https://firegatebiotech.com/2025
FG-001: Integrated Triplet Immunotherapy for Functional HIV Cure
FG-002: Triplet Immunologic Modulation in Oncology — NF-κB / IL-1Ra Axis
FG-003: Neuro-Immune Repair Triplet — Concept and Combination Framework
CCR5 Antagonists & Triplet Immunotherapy Synergy in HIV
HIV Cure Pathways — Functional-Cure Framework Overview
FG-003 Neuro-Immune Repair Triplet — IP & Combination Strategy
— Jeremiah 51:36